comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 15:22:58 - browse：8187

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： FDA advisers back CAR

WSS

Why scientists need input from humanists on sensitive research

Why scientists need input from humanists on sensitive research

Feds fine Medicare Advantage plans for overcharging members

Steward Health Care Massachusetts hospitals face fiscal disaster

How to make Best Hospitals ratings actually useful for patients

AstraZeneca challenges Medicare drug negotiation program

focus

comprehensive

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Change Healthcare outage fallout shows need for new oversight

ChatGPT in medicine: STAT answers readers' burning questions

John Green on his newest strategy for fighting tuberculosis

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Walensky prepares to leave CDC — and Congress — behind

As AI in medicine takes off, can 'human in the loop' prevent harm?

Apple is now the first public company to be valued at $3 trillion

What do new weight loss drugs mean for bariatric surgery?

explore

What do new weight loss drugs mean for bariatric surgery?

Neuroscience startup Neumora files for IPO

Radiation, mainstay of cancer treatment, begins a fade

RaDonda Vaught links Vanderbilt hospital issues to patient death

Steward Health Care Massachusetts hospitals face fiscal disaster

First U.S. drug developed to treat liver disease MASH is approved

knowledge

Wikipedia

hotspot

focus